Lindy Biosciences is a development-stage therapeutics company focused on protein therapeutic formulations. Founded in 2017 and based in Research Triangle Park, the company is led by founder and CEO Deborah Bitterfield. Bitterfield holds a PhD in materials science from Duke University and previously led scientific operations and project management at Southeast Techinventures. The company filed a Form D reporting it has raised $547,000 in equity and is offering a total of $1.6 million. Lindy previously raised $150,000 in 2018. The Form D did not specify how the company intends to use the proceeds. Lindy Biosciences is a Durham-based, development-stage company that produces protein therapeutic formulations. Its core technology, microglassification, produces spherical, dense, stable particles of therapeutic proteins for solid injectable formulations such as high-concentration suspensions or encapsulation for controlled release. The company is developing a high-dose protein suspension suitable for subcutaneous injection that, the company says, will decrease administration costs, increase patient comfort and compliance, and enable high-dose molecules to reach the market. Lindy is led by CEO Deborah Bitterfield. According to an SEC filing, the company raised $150,000 from a single investor. The article notes the SEC filing context and references the Reg D/Form D filing process for offerings relying on that exemption.

Total raised

$151M

Funding rounds

2

Latest round

Equity

Latest activity

Jan 2019